StockData
Aytu BioPharma, Inc logo

Aytu BioPharma, Inc (AYTU) stock

AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.00 (0.00%)

Close on Nov 18, 2026Market cap $28.91MP/E –Yield –

Aytu BioPharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Aytu BioPharma's revenue for the twelve months ending Jun 30, 2026 was $57.57M, down 13.3% year over year. For fiscal 2026 it was $57.57M, down 13.3% from the year before. Over ten years it grew 36.5% a year on average. The highest annual figure on record is $107.40M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2026Jun 30, 2026$57.57M-13.3%
FY2025Jun 30, 2025$66.38M+1.8%
FY2024Jun 30, 2024$65.18M-39.3%
FY2023Jun 30, 2023$107.40M+11.1%
FY2022Jun 30, 2022$96.67M+47.3%
FY2021Jun 30, 2021$65.63M+137.5%
FY2020Jun 30, 2020$27.63M+277.5%
FY2019Jun 30, 2019$7.32M+100.0%
FY2018Jun 30, 2018$3.66M+13.6%
FY2017Jun 30, 2017$3.22M+25.7%
FY2016Jun 30, 2016$2.56M+878.8%
FY2015Jun 30, 2015$261.78K+14859.0%
FY2013Aug 31, 2013$1.75K0.0%
FY2012Aug 31, 2012$1.75K–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026$16.11M+6.4%
Q3 FY2026CQ1 2026Mar 31, 2026$12.41M-32.7%
Q2 FY2026CQ4 2025Dec 31, 2025$15.17M-6.5%
Q1 FY2026CQ3 2025Sep 30, 2025$13.89M-16.2%
Q4 FY2025CQ2 2025Jun 30, 2025$15.14M+3.7%
Q3 FY2025CQ1 2025Mar 31, 2025$18.45M+31.6%
Q2 FY2025CQ4 2024Dec 31, 2024$16.22M-13.5%
Q1 FY2025CQ3 2024Sep 30, 2024$16.57M-7.0%
Q4 FY2024CQ2 2024Jun 30, 2024$14.59M-52.5%
Q3 FY2024CQ1 2024Mar 31, 2024$14.03M-38.3%
Q2 FY2024CQ4 2023Dec 31, 2023$18.75M-28.7%
Q1 FY2024CQ3 2023Sep 30, 2023$17.82M-35.6%
Q4 FY2023CQ2 2023Jun 30, 2023$30.73M+12.0%
Q3 FY2023CQ1 2023Mar 31, 2023$22.73M-6.1%
Q2 FY2023CQ4 2022Dec 31, 2022$26.28M+13.6%
Q1 FY2023CQ3 2022Sep 30, 2022$27.66M+26.3%
Q4 FY2022CQ2 2022Jun 30, 2022$27.45M+16.9%
Q3 FY2022CQ1 2022Mar 31, 2022$24.20M+79.5%
Q2 FY2022CQ4 2021Dec 31, 2021$23.13M+52.7%
Q1 FY2022CQ3 2021Sep 30, 2021$21.90M+62.0%
Q4 FY2021CQ2 2021Jun 30, 2021$23.48M+58.0%
Q3 FY2021CQ1 2021Mar 31, 2021$13.48M+65.3%
Q2 FY2021CQ4 2020Dec 31, 2020$15.15M+377.1%
Q1 FY2021CQ3 2020Sep 30, 2020$13.52M+839.0%
Q4 FY2020CQ2 2020Jun 30, 2020$14.86M+766.2%
Q3 FY2020CQ1 2020Mar 31, 2020$8.16M+243.0%
Q2 FY2020CQ4 2019Dec 31, 2019$3.18M+76.9%
Q1 FY2020CQ3 2019Sep 30, 2019$1.44M+0.6%
Q4 FY2019CQ2 2019Jun 30, 2019$1.72M+85.5%
Q3 FY2019CQ1 2019Mar 31, 2019$2.38M+291.4%
Q2 FY2019CQ4 2018Dec 31, 2018$1.80M+70.8%
Q1 FY2019CQ3 2018Sep 30, 2018$1.43M+33.0%
Q4 FY2018CQ2 2018Jun 30, 2018$925.13K+10.7%
Q3 FY2018CQ1 2018Mar 31, 2018$607.47K-32.0%
Q2 FY2018CQ4 2017Dec 31, 2017$1.05M+32.4%
Q1 FY2018CQ3 2017Sep 30, 2017$1.08M+54.2%
Q4 FY2017CQ2 2017Jun 30, 2017$835.89K–
Q3 FY2017CQ1 2017Mar 31, 2017$893.55K–
Q2 FY2017CQ4 2016Dec 31, 2016$794.17K–
Q1 FY2017CQ3 2016Sep 30, 2016$697.98K–

More Aytu BioPharma figures

See a number that looks wrong?